Nakyoung Nam, MD
Allergy & Immunology · Dacula, GANPI 1518167436
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,097, 2.8 times the $756 reported in 2019.
Across 314 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$911
- GSK$887
- Amgen$699
- Regeneron Healthcare Solutions, Inc.$598
- Sanofi$485
- CSL Behring$373
- plus $3K from 26 others
What the payments were for
- Food & beverage$6,52598%
- Education$1142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $911 |
| GSK | 49 | $887 |
| Amgen | 35 | $699 |
| Regeneron Healthcare Solutions, Inc. | 26 | $598 |
| Sanofi | 17 | $485 |
| CSL Behring | 14 | $373 |
| Novartis | 19 | $355 |
| Pfizer | 16 | $324 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $272 |
| Kaleo, Inc. | 16 | $271 |
| Optinose US, Inc. | 14 | $262 |
| Covis Pharma GmbH | 9 | $200 |
| Grifols USA, LLC | 5 | $92 |
| AbbVie | 4 | $91 |
| Teva Pharmaceuticals USA, Inc. | 5 | $80 |
| Octapharma USA, Inc. | 1 | $78 |
| Genentech USA, Inc. | 3 | $67 |
| Pharming Healthcare, Inc. | 3 | $65 |
| Shire North American Group Inc | 4 | $65 |
| Boehringer Ingelheim | 4 | $65 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Azurity Pharmaceuticals, Inc. | 3 | $53 |
| Hikma Pharmaceuticals USA | 2 | $47 |
| Biocryst US Sales Co., LLC | 2 | $46 |
| Aimmune Therapeutics, Inc. | 2 | $44 |
| Alk-abello, Inc | 2 | $40 |
| Lilly USA, LLC | 1 | $23 |
| Dermavant Sciences, Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Organon | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$100
How this compares
$6,639 in reported general payments places this provider in the 55th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $31,616 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $14,570 |
| Epinephrine | 47 | $11,219 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $7,859 |
| Arnuity ElliptaFluticasone Furoate | 26 | $5,638 |
| Advair DiskusFluticasone Propion/Salmeterol | 11 | $2,019 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $1,744 |
| Azelastine Hcl | 73 | $1,504 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $1,300 |
| Levocetirizine Dihydrochloride | 77 | $760 |
| Ipratropium Bromide | 17 | $449 |
| Fluticasone Propionate | 21 | $278 |
| Montelukast Sodium | 29 | $244 |
| Triamcinolone Acetonide | 11 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $887 | $51,823103 claims |
| Hikma Pharmaceuticals USAEpinephrine | $47 | $11,21947 claims |
| AstraZenecaSymbicort | $911 | $7,85937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Dacula
- Michael BlaissRoswell$1.1M
- Deborah BirxAtlanta$470K
- Tracy BridgesAlbany$364K
- Jack EadesMacon$237K
- Stanley FinemanMarietta$186K
- Robert CartwrightColumbus$169K
- Robert ChrzanowskiColumbus$115K
- Belinda GrahamSmyrna$94K
- Lily HwangRoswell$88K
- Paul RabinowitzAtlanta$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.